tradingkey.logo
๎™ผ
tradingkey.logo
๎™๊ฒ€์ƒ‰
๎™

Aytu Biopharma Inc

AYTU
๎˜ญ๊ด€์‹ฌ ๋ชฉ๋ก์— ์ถ”๊ฐ€
2.230USD
+0.080+3.72%
์ข…๊ฐ€ย 07-31 16:00๏ผˆET๏ผ‰์‹œ์„ธ๋Š” 15๋ถ„ ์ง€์—ฐ๋ฉ๋‹ˆ๋‹ค
23.94M์‹œ๊ฐ€์ด์•ก
์†์‹คP/E TTM

์ž์„ธํ•œ ๋‚ด์šฉ์€ Aytu Biopharma Inc ํšŒ์‚ฌ

Aytu BioPharma, Inc. is a pharmaceutical company focused on commercializing novel therapeutics. The Company's business is focused on its prescription pharmaceutical products sold primarily through third party wholesalers and pharmacies and which primarily consists of two product portfolios. The first consists of two products for the treatment of ADHD: Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets (Adzenys) and Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets. The second consists primarily of Karbinal ER (carbinoxamine maleate extended-release oral suspension), an extended-release first-generation antihistamine suspension containing carbinoxamine indicated to treat numerous allergic conditions, and Poly-Vi-Flor and Tri-Vi-Flor, two complementary prescription fluoride-based supplement product lines containing combinations of fluoride and vitamins in various formulations for infants and children with fluoride deficiency.

Aytu Biopharma Inc ์ •๋ณด

๎™Œ
์ข…๋ชฉ ์ฝ”๋“œ AYTU
ํšŒ์‚ฌ ์ด๋ฆ„Aytu Biopharma Inc
์ƒ์žฅ์ผOct 20, 2017
CEODisbrow (Joshua R)
์ง์› ์ˆ˜82
์œ ํ˜•Ordinary Share
ํšŒ๊ณ„ ์—ฐ๋„ ์ข…๋ฃŒOct 20
์ฃผ์†Œ7900 E. Union Avenue
๋„์‹œDENVER
์ฆ๊ถŒ ๊ฑฐ๋ž˜์†ŒNASDAQ OMX - NASDAQ BASIC
๊ตญ๊ฐ€United States of America
์šฐํŽธ ๋ฒˆํ˜ธ80237
์ „ํ™”17204376580
์›น์‚ฌ์ดํŠธhttps://aytubio.com/
์ข…๋ชฉ ์ฝ”๋“œ AYTU
์ƒ์žฅ์ผOct 20, 2017
CEODisbrow (Joshua R)

Aytu Biopharma Inc์˜ ํšŒ์‚ฌ ์ž„์›์ง„

๎™Œ
์ด๋ฆ„
์ด๋ฆ„/์ง์œ„
์ง์œ„
์ฃผ์‹ ๋ณด์œ 
๋ณ€๋™
Mr. Jarrett T. (Josh) Disbrow
Mr. Jarrett T. (Josh) Disbrow
Chief Business Officer
Chief Business Officer
61.57K
+52.15%
Mr. Ryan J. Selhorn, CPA
Mr. Ryan J. Selhorn, CPA
Chief Financial Officer, Treasurer, Corporate Secretary
Chief Financial Officer, Treasurer, Corporate Secretary
49.74K
+67.83%
Mr. Greg Pyszczymuka
Mr. Greg Pyszczymuka
Chief Commercial Officer
Chief Commercial Officer
36.10K
+34.05%
Mr. Carl C. Dockery
Mr. Carl C. Dockery
Independent Director
Independent Director
21.15K
+47.28%
Ms. Vivian H. Liu
Ms. Vivian H. Liu
Independent Director
Independent Director
19.82K
+50.44%
Mr. Joshua R. (Josh) Disbrow
Mr. Joshua R. (Josh) Disbrow
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. John A. Donofrio, Jr.
Mr. John A. Donofrio, Jr.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Abhinav (Abi) Jian
Mr. Abhinav (Abi) Jian
Independent Director
Independent Director
--
--
์ด๋ฆ„
์ด๋ฆ„/์ง์œ„
์ง์œ„
์ฃผ์‹ ๋ณด์œ 
๋ณ€๋™
Mr. Jarrett T. (Josh) Disbrow
Mr. Jarrett T. (Josh) Disbrow
Chief Business Officer
Chief Business Officer
61.57K
+52.15%
Mr. Ryan J. Selhorn, CPA
Mr. Ryan J. Selhorn, CPA
Chief Financial Officer, Treasurer, Corporate Secretary
Chief Financial Officer, Treasurer, Corporate Secretary
49.74K
+67.83%
Mr. Greg Pyszczymuka
Mr. Greg Pyszczymuka
Chief Commercial Officer
Chief Commercial Officer
36.10K
+34.05%
Mr. Carl C. Dockery
Mr. Carl C. Dockery
Independent Director
Independent Director
21.15K
+47.28%
Ms. Vivian H. Liu
Ms. Vivian H. Liu
Independent Director
Independent Director
19.82K
+50.44%
Mr. Joshua R. (Josh) Disbrow
Mr. Joshua R. (Josh) Disbrow
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--

์ž์ฃผ ๋ฌป๋Š” ์งˆ๋ฌธ

Aytu Biopharma Inc์˜ ์ƒ์œ„ 5๋Œ€ ์ฃผ์ฃผ๋Š” ๋ˆ„๊ตฌ์ธ๊ฐ€์š”?

๎™Œ
Aytu Biopharma Inc์˜ ์ƒ์œ„ 5๋Œ€ ์ฃผ์ฃผ๋Š” ๋‹ค์Œ๊ณผ ๊ฐ™์Šต๋‹ˆ๋‹ค: Mr. Jarrett T. (Josh) Disbrow

Aytu Biopharma Inc(AYTU)์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•œ ๊ธฐ๊ด€์€ ๋ช‡ ๊ฐœ์ž…๋‹ˆ๊นŒ?

๎™Œ
2026Q1 ๊ธฐ์ค€์œผ๋กœ, Aytu Biopharma Inc์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•œ ๊ธฐ๊ด€์€ ์ด 69๊ณณ์ด๋ฉฐ, ์ด๋“ค์ด ๋ณด์œ ํ•œ ์ฃผ์‹์˜ ์ด ๊ฐ€์น˜๋Š” ์•ฝ 3.87M๋กœ ์ „์ฒด ๋ฐœํ–‰ ์ฃผ์‹์˜ 36.10%๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค. ์ด๋Š” 2025Q4 ๋Œ€๋น„ -493525.00 ์ฆ๊ฐ€ํ•œ ์ˆ˜์น˜์ž…๋‹ˆ๋‹ค.

Aytu Biopharma Inc์˜ ์ตœ๋Œ€ ์ˆ˜์ต์›์€ ๋ฌด์—‡์ธ๊ฐ€์š”?

๎™Œ
2026Q1 ๊ธฐ์ค€, Aytu Biopharma Inc์˜ ADHD portfolio ๋ถ€๋ฌธ์ด ๊ฐ€์žฅ ๋†’์€ ๋งค์ถœ์„ ๊ธฐ๋กํ–ˆ์œผ๋ฉฐ, ๊ธˆ์•ก์€ 13.22M๋กœ ์ „์ฒด ๋งค์ถœ์˜ 87.15%๋ฅผ ์ฐจ์ง€ํ–ˆ์Šต๋‹ˆ๋‹ค.
tradingkey.logo
์œ„ํ—˜ ๊ฒฝ๊ณ : ์ €ํฌ ์›น์‚ฌ์ดํŠธ์™€ ๋ชจ๋ฐ”์ผ ์•ฑ์€ ํŠน์ • ํˆฌ์ž ์ƒํ’ˆ์— ๋Œ€ํ•œ ์ผ๋ฐ˜์ ์ธ ์ •๋ณด๋งŒ์„ ์ œ๊ณตํ•ฉ๋‹ˆ๋‹ค. Finsights๋Š” ์žฌ์ •์  ์กฐ์–ธ์ด๋‚˜ ํˆฌ์ž ์ƒํ’ˆ์— ๋Œ€ํ•œ ์ถ”์ฒœ์„ ์ œ๊ณตํ•˜์ง€ ์•Š์œผ๋ฉฐ, ์ด๋Ÿฌํ•œ ์ •๋ณด ์ œ๊ณต์ด Finsights๊ฐ€ ๊ธˆ์œต ์กฐ์–ธ์ด๋‚˜ ์ถ”์ฒœ์„ ์ œ๊ณตํ•˜๋Š” ๊ฒƒ์œผ๋กœ ํ•ด์„๋˜์–ด์„œ๋Š” ์•ˆ ๋ฉ๋‹ˆ๋‹ค.
ํˆฌ์ž ์ƒํ’ˆ์€ ํˆฌ์ž ์›๊ธˆ ์†์‹ค์„ ํฌํ•จํ•œ ์ƒ๋‹นํ•œ ํˆฌ์ž ์œ„ํ—˜์— ๋…ธ์ถœ๋˜์–ด ์žˆ์œผ๋ฉฐ, ๋ชจ๋“  ์‚ฌ๋žŒ์—๊ฒŒ ์ ํ•ฉํ•˜์ง€ ์•Š์„ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค. ํˆฌ์ž ์ƒํ’ˆ์˜ ๊ณผ๊ฑฐ ์„ฑ๊ณผ๋Š” ๋ฏธ๋ž˜ ์„ฑ๊ณผ๋ฅผ ๋ณด์žฅํ•˜์ง€ ์•Š์Šต๋‹ˆ๋‹ค.
Finsights๋Š” ์ œ3์ž ๊ด‘๊ณ ์ฃผ๋‚˜ ์ œํœด์‚ฌ๊ฐ€ ์ €ํฌ ์›น์‚ฌ์ดํŠธ๋‚˜ ๋ชจ๋ฐ”์ผ ์•ฑ ๋˜๋Š” ๊ทธ ์ผ๋ถ€์— ๊ด‘๊ณ ๋ฅผ ๊ฒŒ์žฌํ•˜๊ฑฐ๋‚˜ ์ „๋‹ฌํ•  ์ˆ˜ ์žˆ๋„๋ก ํ—ˆ์šฉํ•  ์ˆ˜ ์žˆ์œผ๋ฉฐ, ์‚ฌ์šฉ์ž๊ฐ€ ๊ด‘๊ณ ์™€ ์ƒํ˜ธ์ž‘์šฉํ•˜๋Š” ๋ฐฉ์‹์— ๋”ฐ๋ผ ์ด๋“ค๋กœ๋ถ€ํ„ฐ ๋ณด์ƒ์„ ๋ฐ›์„ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.
ยฉ ์ €์ž‘๊ถŒ: FINSIGHTS MEDIA PTE. LTD. ๋ชจ๋“  ๊ถŒ๋ฆฌ ๋ณด์œ